Delayed anaphylaxis to red meat in patients with IgE specific for galactose alpha-1,3-galactose (alpha-gal)

Curr Allergy Asthma Rep. 2013 Feb;13(1):72-7. doi: 10.1007/s11882-012-0315-y.

Abstract

Anaphylaxis is a severe allergic reaction that can be rapidly progressing and fatal. In instances where the triggering allergen is not known, establishing the etiology of anaphylaxis is pivotal to long-term risk management. Our recent work has identified a novel IgE antibody (Ab) response to a mammalian oligosaccharide epitope, galactose-alpha-1,3-galactose (alpha-gal), that has been associated with two distinct forms of anaphylaxis: (1) immediate onset anaphylaxis during first exposure to intravenous cetuximab, and (2) delayed onset anaphylaxis 3-6 h after ingestion of mammalian food products (e.g., beef and pork). The results of our studies strongly suggest that tick bites are a cause, if not the only significant cause, of IgE Ab responses to alpha-gal in the southern, eastern and central United States. Patients with IgE Ab to alpha-gal continue to emerge and, increasingly, these cases involve children. This IgE Ab response cross-reacts with cat and dog but does not appear to pose a risk for asthma; however, it may impair diagnostic testing in some situations.

Publication types

  • Research Support, N.I.H., Extramural
  • Review

MeSH terms

  • Allergens / immunology*
  • Anaphylaxis / etiology*
  • Anaphylaxis / immunology
  • Animals
  • Antibodies, Monoclonal / adverse effects
  • Antibodies, Monoclonal, Humanized
  • Asthma / immunology
  • Cetuximab
  • Cross Reactions / immunology
  • Disaccharides / immunology*
  • Epitopes / immunology
  • Food Hypersensitivity / etiology*
  • Food Hypersensitivity / immunology
  • Humans
  • Immunoglobulin E / blood*
  • Insect Bites and Stings / immunology
  • Meat / adverse effects*
  • Ticks

Substances

  • Allergens
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Disaccharides
  • Epitopes
  • galactosyl-(1-3)galactose
  • Immunoglobulin E
  • Cetuximab